At a glance
The Therapeutic Idea Award funds new, innovative, high-risk research aimed at ALS drug or therapy discovery, including investigational drug and medical device studies. Eligible applicants include extramural and intramural U.S. Department of War organizations, as well as foreign and domestic, for-profit and nonprofit, public and private organizations; awards are made to eligible organizations, not individuals. The program expects to fund about 12 awards with total costs capped at $840,000 per award, and the maximum period of performance is two years. Cost sharing is not required. There are no geographic restrictions stated, but clinical trials are not allowed, and projects involving animal models must follow specified research standards.
What it funds
Official description from grants.gov
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Idea Award (TIA) supports new, innovative, high-risk, high-gain ideas aimed at amyotrophic lateral sclerosis (ALS) drug or therapy discovery. The studies supported by this award mechanism are expected to be hypothesis-driven and generate preliminary data for future avenues of therapeutic investigation. Distinctive Features: Potential impact and innovation are important features of the TIA. Applications may demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis. While the inclusion of preliminary data is not prohibited, the strength of the application should rely on the approach.
Who can apply
- Unrestricted